Is Buying VITALITY BIOPHARMA INC (OTCMKTS:VBIO), Having Lower Short Interest a Winning Strategy?

March 14, 2018 - By Dolores Ford

The stock of VITALITY BIOPHARMA INC (OTCMKTS:VBIO) registered a decrease of 9.1% in short interest. VBIO’s total short interest was 282,800 shares in March as published by FINRA. Its down 9.1% from 311,100 shares, reported previously. With 291,900 shares average volume, it will take short sellers 1 days to cover their VBIO’s short positions. The short interest to VITALITY BIOPHARMA INC’s float is 1.52%.

The stock decreased 0.54% or $0.04 during the last trading session, reaching $1.81. About 73,445 shares traded. Vitality Biopharma, Inc. (OTCMKTS:VBIO) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Vitality Biopharma, Inc. focuses on the development of cannabinoid pharmaceuticals for the treatment of neurological and inflammatory disorders in the United States. The company has market cap of $43.80 million. The Company’s products in pipeline include VITA-100, an oral cannabinoid formulation that is used for the acute treatment of inflammatory bowel disease and narcotic bowel syndrome; and VITA-210, a cannabinoid formulation, which is in preclinical studies for use in the chronic treatment of neuropathic pain, irritable bowel syndrome, muscle spasticity in multiple sclerosis, and opioid-induced bowel dysfunction. It currently has negative earnings. The firm was formerly known as Stevia First Corp. and changed its name to Vitality Biopharma, Inc. in July 2016.

More notable recent Vitality Biopharma, Inc. (OTCMKTS:VBIO) news were published by: which released: “Vitality Biopharma Publishes Scientific Data on Discovery of Cannabinoid …” on February 01, 2017, also with their article: “Vitality Biopharma Announces Positive Results for Multiple Cannabinoid Drug …” published on October 19, 2017, published: “Vitality Biopharma Releases Positive Results for Treatment of Inflammatory …” on July 19, 2017. More interesting news about Vitality Biopharma, Inc. (OTCMKTS:VBIO) were released by: and their article: “Vitality Biopharma Inc.” published on May 17, 2017 as well as‘s news article titled: “Vitality Biopharma Receives DEA Approval for Cannabinoid Pharma Development …” with publication date: December 21, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: